Makale Arama

Aim: It was aimed to investigate  the relationship of disease clinical stage between the maximum diameter of primer lesion (LEGÇ), maximum of standardized uptake value (SUVmax), mean of standardized uptake value (SUVmean), tumor volüme (TV) and total lesion glycolysis (TLG) values derived from positron emission tomography/computed tomography (PET/CT) images.

Method: The information of 130 lung cancer patients diagnosed histopathologically between 01.01.2012 and 31.12.2014 in Necmettin Erbakan University Nuclear Medicine Department of Meram Medical Faculty scanned for PET-CT for lung cancer diagnosis and staging,  were included in this study. The values of the maximum diameter of primer lesion, SUVmax, SUVmean, TLG and MTV derived from PET-CT scanning and their histopathological subtypes, other clinical and radyological information of patients were noted. The non-small cell lung cancer patients were graded according to tumor diameter, nodal and involvement metastasis (TNM) staging system using clinical information, PET-CT and other radyological test results if any. On the other hand, the small cell carcinoma diagnosed were categorised as limited or extensive stage.

Findings: In this study, the mean age of 118 men and 12 women,  totally 130 patients, was evaluated  63,46 ±9,96 ( range 40-87 age ). The patients were classified as 106 non-small cell lung Cancer (NSCLC) (81.5%) ve 24 small cell lung cancer (SCLC) (18.5%).  The  histopathologically diagnosed NSCLC patients were consists of  62 squamous cell cancers, 39 adeno cancers, and 5  other types (3 carcinoid tumors, 1 large cell cancer and 1 sarcomatoid tumor). 

Results: In our study, it was observed that there was no significant relationship between the maximum diameter of the lesion, SUVmax, SUVmean, MTV and TLG values among SCLC and NSCLC patients. Additionally, it was also found that there was no correlation between these parameters and the SCLC stage.  The maximum diameter of the lesion, SUVmax, SUVmean, MTV and TLG parameters were related with stage.

Conclusion: Higher SUVmax, SUVmean, TV, and TLG values of the primary tumor were determined to predict the more advanced clinical stage in NSCLC. This relationship between metabolic parameters and the clinical stage suggest that PET / CT may be valuable in terms of providing prognostic information in NSCLC.

Occult breast cancer is a type of cancer with no symptoms found upon physical examination on the breasts or which can not be radiologically shown. It generally manifests itself with axillary metastasis with no known primary tumor. Breast cancer in males is rarely seen. Occult breast cancer, on the other hand, is even rarer and only case reports were found in literature. A 46-year-old male patient had excisional biopsy at another medical facility because of a palpable mass on his right armpit. The pathological diagnosis had stated that the patient had adenocarcinoma metastasis with symptoms implying an infiltrative ductal carcinoma metastasis of the breast. Abdominal and thoracic tomography, upper and lower gastrointestinal system endoscopy procedures were performed on the patient in order to determine the primary focus. Breast ultrasonography, breast magnetic resonance imaging and positron emission tomography were also performed. Upon not being able to detect any positive findings, the patient was considered to have occult breast carcinoma and modified radical mastectomy was performed. In conclusion, in the presence of metastatic lymph node with no known primary tumor in the axillary, the possibility of occult breast cancer should be taken into consideration even if the patient is male.

Elastofibroma dorsi is a rare, benign tumor, characterized by fibroblastic proliferation and accumulation of abnormal elastic fibers. It is located in the subscapular region between the scapula and the thoracic wall. Especially, the suspicion of soft tissue sarcoma may produce anxiety. Magnetic resonance imaging and computed tomography findings are usually typical; and, positron emission tomography may also contribute to the diagnosis. Diagnosis can be made easily with typical localization and imaging findings. We present clinical and imaging findings in three cases of elastofibroma dorsi.

Aim

The decision to start treatment in sarcoidosis is made based on clinical and radiological findings and changes in pulmonary function test findings during follow-up, and more useful tools are needed in treatment management. F-18 fluorodeoxyglucose (18F-FDG) positron required important tomography / computed tomography (PET/CT) contains important information about the extent of sarcoidosis. On the other hand, the neutrophil/lymphocyte ratio (NLR) opens as a good prognostic marker for tissue-related inflammation. This study evaluated the relationship between the 18F-FDG PET/CT findings of sarcoidosis and NLR and other clinical findings.

Material and methods

The data of the patient who was diagnosed with sarcoidosis after 18F-FDG PET/CT examination in our clinic were retrospectively reviewed. Patients' age, gender, NLR values, smoking status, extrathoracic involvement and symptoms, and 18F-FDG PET/CT findings were compared.

Results

This study consisted of 41 patients. There was a strong correlation between NLR and whole body total lesion glycolysis (TLG), and moderate correlation between  MAIA and NLR (r values: 0.852, 0.660, both of them p value: <0.001, respectively). There was a significant difference between the groups showing only thoracic involvement and additional extrathoracic involvement with MAIA, TLG and NLR values (p values,: 0.002, 0.001 and, 0.003, respectively). In the classification made according to the symptoms of the patients, there was no significant difference between the groups with SUVmax, MAIA, TLG and NLR values. Median values were found to be significantly higher in the elderly group (p values: 0.037 and 0.040, respectively). In the classification made according to gender; there was no significant difference in both PET/CT parameters and NLR values.

Conclusion

The close relationship between the NLR value, which is accepted as a prognostic indicator in sarcoidosis, and the 18F-FDG PET / CT findings which show the involvement of the disease in the whole body, may provide the clinician with significant benefits in treatment management.

Aim: This study aimed to evaluate the incidence of hypermetabolic axillary lymph nodes due to COVID-19
vaccines and the factors affecting hypermetabolic axillary lymph nodes in F18-fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography (PET/CT) in on cology patients.
Patients and Methods: Among the patients who underwent FDG PET/CT in our institution between
January 15, 2021, and June 15, 2021, those who received one or two doses of COVID-19 vaccine
(CoronaVac or Biontech) were included in the study. Presence and number of ipsilateral hypermetabolic
axillary lymph nodes, FDG uptake, and whether there was a difference between these data after the 1st
and 2nd vaccination were investigated.
Results: Unilateral hypermetabolic axillary lymph nodes was observed in 9.9% (18/182) of the patients
[9.6% (9/94) after 1st dose, 10.2% (9/88) after 2nd dose] vaccinated with CoronaVac; It was detected in
37.5% (9/24) of the patients [35% (7/20) after 1st dose, 50% (2/4) after 2nd dose] who vaccinated with
Biontech. A negative correlation was found between the presence of hypermetabolic axillary lymph nodes
and age in patients who vaccinated with CoronaV ac.
Conclusion: The frequency of hipermetabolik aksiller lenf nodu after CoronaVac was lower than that
observed after mRNA vaccines, a small group of patients in our study, and lower than reported in the
literature. However, the statistical difference could not be evaluated due to the insufficient number of
patients in the Biontech group. A brief history of vaccination is recommended before FDG PET/CT to
reduce false positives. The potential role of FDG PET/CT in comparing the efficacy of vaccines produced
with dif ferent biotechnologies should be searched in studies with large r patient populations.

Aim: We aimed to retrospectively analyze and present the findings of patients diagnosed with esophageal
cancer and staged using 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed
Tomography (PET/CT) imaging.
Patients and Methods: Thirty-seven patients diagnosed with esophagus who were staged with 18F-FDG
PET/CT in our hospital between February 2015 and February 2020 were included in this study. Patients'
age, gender, localization of the primary tumor and 18F-FDG PET/CT maximum standardized uptake value
(SUVmax), findings of metastases to mediastinal, abdominal and cervical lymph nodes, lung, liver, bone and
other areas were retrospectively evaluated as.
Results: The meanage of the patients was 66,97 ± 14,54 years. 20 patients (54%) were male, 17 patients
(46%) were female. 10 patients (27%) had upper esophagus tumors, 23 patients (62%) had lower esophagus
tumors, 4 patients had middle esophageal tumors (11%). The pathological diagnosis of 23 patients was
squamous cell ca, 14 patients were adeno ca. The mean of primary tumor SUV max was measured as 14,09
± 6,36 in all patients. The mean primary tumor SUVmax of the patients diagnosed with squamous ca was
14,51 ± 6,63, and the mean of primary tumor SUV max of the patients diagnosed with adeno ca was found to
be 13,40 ± 6,03. Progression was observed in 7 of 9 patients whose treatment and follow-ups were continued
in our hospital, and regression was observed in 2 of them.
Conclusion: In the initial staging of patients diagnosed with esophageal ca, 18F-FDG PET/CT is an
increasingly useful imaging method. Our study supports this.